Levosimendan Fmk (Levosimendan)

Levosimendan sensitises cardiac troponin C to calcium, which enhances the strength of heart muscle contraction without increasing intracellular calcium. At the same time, it opens ATP‑sensitive potassium channels in vascular smooth muscle, causing vasodilation that lowers both preload and afterload.

The dosing regimen for Levosimendan is individualized by the prescribing clinician based on the patient’s clinical status, weight, and renal function. The prescriber determines the infusion rate, duration, and any loading dose required for safe and effective therapy.

Safety data for Levosimendan in pregnant or lactating women are limited. Because potential risks cannot be ruled out, the drug should be used only if the potential benefit justifies the potential risk to the fetus or infant, and it is generally avoided unless absolutely necessary.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Unlike traditional catecholamine inotropes, Levosimendan increases contractility without raising intracellular calcium, which may reduce the risk of arrhythmias. Its additional vasodilatory effect can improve hemodynamics more comprehensively, but clinicians must balance this against a higher incidence of hypotension compared with some alternatives.

Levosimendan should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Before use, the product should be allowed to reach room temperature if required for reconstitution, and all handling should follow aseptic techniques to maintain sterility.

Levosimendan is administered intravenously, typically as an infusion over a period of 24 hours after an optional loading dose. The infusion is given through a dedicated IV line under continuous monitoring of blood pressure, heart rate, and cardiac output by qualified healthcare professionals.

The most serious risks include severe hypotension, ventricular arrhythmias, myocardial ischemia, and rare cases of sudden cardiac death. Patients should be closely monitored for changes in blood pressure, rhythm disturbances, and signs of chest pain throughout the infusion and for several hours afterward.

Levosimendan is contraindicated in patients with uncontrolled severe hypotension, recent myocardial infarction, severe obstructive valvular disease, or known hypersensitivity to the drug. Caution is also advised in individuals with significant renal or hepatic impairment, and it should be avoided in pregnancy unless clearly justified.